 | • レポートコード：MRC2-11QY08841 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はパフォーマンス向上薬のグローバル市場について調査・分析したレポートです。種類別（丸薬、注射、パッチ）市場規模、用途別（アスリート、ボディビルダー、学生、軍隊）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別パフォーマンス向上薬の競争状況、市場シェア ・世界のパフォーマンス向上薬市場：種類別市場規模 2015年-2020年（丸薬、注射、パッチ） ・世界のパフォーマンス向上薬市場：種類別市場規模予測 2021年-2026年（丸薬、注射、パッチ） ・世界のパフォーマンス向上薬市場：用途別市場規模 2015年-2020年（アスリート、ボディビルダー、学生、軍隊） ・世界のパフォーマンス向上薬市場：用途別市場規模予測 2021年-2026年（アスリート、ボディビルダー、学生、軍隊） ・北米のパフォーマンス向上薬市場分析：米国、カナダ ・ヨーロッパのパフォーマンス向上薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのパフォーマンス向上薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のパフォーマンス向上薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのパフォーマンス向上薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Taj Pharmaceuticals、Balkan Pharmaceuticals、Bayer、AstraZeneca、Novo Nordisk、BrainAlert、Douglas Laboratories、Onnit Labs、Eli Lilly And Company ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Performance-enhancing drugs (PED), are substances that are used to improve any form of activity performance in humans.
A well-known example of PED involves doping in sport, where banned physical performance–enhancing drugs are used by athletes and bodybuilders. Athletic performance-enhancing substances are sometimes referred to as ergogenic aids. Cognitive performance-enhancing drugs, commonly called nootropics, are sometimes used by students to improve academic performance. Performance-enhancing substances are also used by military personnel to enhance combat performance.
Market Analysis and Insights: Global Performance Enhancing Drugs Market
The global Performance Enhancing Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Performance Enhancing Drugs Scope and Market Size
Performance Enhancing Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Performance Enhancing Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Performance Enhancing Drugs market is segmented into
Pills
Injections
Patches
Segment by Application, the Performance Enhancing Drugs market is segmented into
Athletes
Body Builders
Students
Militaries
Regional and Country-level Analysis
The Performance Enhancing Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Performance Enhancing Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Performance Enhancing Drugs Market Share Analysis
Performance Enhancing Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Performance Enhancing Drugs business, the date to enter into the Performance Enhancing Drugs market, Performance Enhancing Drugs product introduction, recent developments, etc.
The major vendors covered:
Taj Pharmaceuticals
Balkan Pharmaceuticals
Bayer
AstraZeneca
Novo Nordisk
BrainAlert
Douglas Laboratories
Onnit Labs
Eli Lilly And Company
1 Study Coverage
1.1 Performance Enhancing Drugs Product Introduction
1.2 Market Segments
1.3 Key Performance Enhancing Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Performance Enhancing Drugs Market Size Growth Rate by Type
1.4.2 Pills
1.4.3 Injections
1.4.4 Patches
1.5 Market by Application
1.5.1 Global Performance Enhancing Drugs Market Size Growth Rate by Application
1.5.2 Athletes
1.5.3 Body Builders
1.5.4 Students
1.5.5 Militaries
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Performance Enhancing Drugs Market Size, Estimates and Forecasts
2.1.1 Global Performance Enhancing Drugs Revenue 2015-2026
2.1.2 Global Performance Enhancing Drugs Sales 2015-2026
2.2 Global Performance Enhancing Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Performance Enhancing Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Performance Enhancing Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Performance Enhancing Drugs Competitor Landscape by Players
3.1 Performance Enhancing Drugs Sales by Manufacturers
3.1.1 Performance Enhancing Drugs Sales by Manufacturers (2015-2020)
3.1.2 Performance Enhancing Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Performance Enhancing Drugs Revenue by Manufacturers
3.2.1 Performance Enhancing Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Performance Enhancing Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Performance Enhancing Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Performance Enhancing Drugs Revenue in 2019
3.2.5 Global Performance Enhancing Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Performance Enhancing Drugs Price by Manufacturers
3.4 Performance Enhancing Drugs Manufacturing Base Distribution, Product Types
3.4.1 Performance Enhancing Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Performance Enhancing Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Performance Enhancing Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Performance Enhancing Drugs Market Size by Type (2015-2020)
4.1.1 Global Performance Enhancing Drugs Sales by Type (2015-2020)
4.1.2 Global Performance Enhancing Drugs Revenue by Type (2015-2020)
4.1.3 Performance Enhancing Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Performance Enhancing Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Performance Enhancing Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Performance Enhancing Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Performance Enhancing Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Performance Enhancing Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Performance Enhancing Drugs Market Size by Application (2015-2020)
5.1.1 Global Performance Enhancing Drugs Sales by Application (2015-2020)
5.1.2 Global Performance Enhancing Drugs Revenue by Application (2015-2020)
5.1.3 Performance Enhancing Drugs Price by Application (2015-2020)
5.2 Performance Enhancing Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Performance Enhancing Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Performance Enhancing Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Performance Enhancing Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Performance Enhancing Drugs by Country
6.1.1 North America Performance Enhancing Drugs Sales by Country
6.1.2 North America Performance Enhancing Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Performance Enhancing Drugs Market Facts & Figures by Type
6.3 North America Performance Enhancing Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Performance Enhancing Drugs by Country
7.1.1 Europe Performance Enhancing Drugs Sales by Country
7.1.2 Europe Performance Enhancing Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Performance Enhancing Drugs Market Facts & Figures by Type
7.3 Europe Performance Enhancing Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Performance Enhancing Drugs by Region
8.1.1 Asia Pacific Performance Enhancing Drugs Sales by Region
8.1.2 Asia Pacific Performance Enhancing Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Performance Enhancing Drugs Market Facts & Figures by Type
8.3 Asia Pacific Performance Enhancing Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Performance Enhancing Drugs by Country
9.1.1 Latin America Performance Enhancing Drugs Sales by Country
9.1.2 Latin America Performance Enhancing Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Performance Enhancing Drugs Market Facts & Figures by Type
9.3 Central & South America Performance Enhancing Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Performance Enhancing Drugs by Country
10.1.1 Middle East and Africa Performance Enhancing Drugs Sales by Country
10.1.2 Middle East and Africa Performance Enhancing Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Performance Enhancing Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Performance Enhancing Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Taj Pharmaceuticals
11.1.1 Taj Pharmaceuticals Corporation Information
11.1.2 Taj Pharmaceuticals Description and Business Overview
11.1.3 Taj Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Taj Pharmaceuticals Performance Enhancing Drugs Products Offered
11.1.5 Taj Pharmaceuticals Related Developments
11.2 Balkan Pharmaceuticals
11.2.1 Balkan Pharmaceuticals Corporation Information
11.2.2 Balkan Pharmaceuticals Description and Business Overview
11.2.3 Balkan Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Balkan Pharmaceuticals Performance Enhancing Drugs Products Offered
11.2.5 Balkan Pharmaceuticals Related Developments
11.3 Bayer
11.3.1 Bayer Corporation Information
11.3.2 Bayer Description and Business Overview
11.3.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Bayer Performance Enhancing Drugs Products Offered
11.3.5 Bayer Related Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Corporation Information
11.4.2 AstraZeneca Description and Business Overview
11.4.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.4.4 AstraZeneca Performance Enhancing Drugs Products Offered
11.4.5 AstraZeneca Related Developments
11.5 Novo Nordisk
11.5.1 Novo Nordisk Corporation Information
11.5.2 Novo Nordisk Description and Business Overview
11.5.3 Novo Nordisk Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Novo Nordisk Performance Enhancing Drugs Products Offered
11.5.5 Novo Nordisk Related Developments
11.6 BrainAlert
11.6.1 BrainAlert Corporation Information
11.6.2 BrainAlert Description and Business Overview
11.6.3 BrainAlert Sales, Revenue and Gross Margin (2015-2020)
11.6.4 BrainAlert Performance Enhancing Drugs Products Offered
11.6.5 BrainAlert Related Developments
11.7 Douglas Laboratories
11.7.1 Douglas Laboratories Corporation Information
11.7.2 Douglas Laboratories Description and Business Overview
11.7.3 Douglas Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Douglas Laboratories Performance Enhancing Drugs Products Offered
11.7.5 Douglas Laboratories Related Developments
11.8 Onnit Labs
11.8.1 Onnit Labs Corporation Information
11.8.2 Onnit Labs Description and Business Overview
11.8.3 Onnit Labs Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Onnit Labs Performance Enhancing Drugs Products Offered
11.8.5 Onnit Labs Related Developments
11.9 Eli Lilly And Company
11.9.1 Eli Lilly And Company Corporation Information
11.9.2 Eli Lilly And Company Description and Business Overview
11.9.3 Eli Lilly And Company Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Eli Lilly And Company Performance Enhancing Drugs Products Offered
11.9.5 Eli Lilly And Company Related Developments
11.1 Taj Pharmaceuticals
11.1.1 Taj Pharmaceuticals Corporation Information
11.1.2 Taj Pharmaceuticals Description and Business Overview
11.1.3 Taj Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Taj Pharmaceuticals Performance Enhancing Drugs Products Offered
11.1.5 Taj Pharmaceuticals Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Performance Enhancing Drugs Market Estimates and Projections by Region
12.1.1 Global Performance Enhancing Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Performance Enhancing Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Performance Enhancing Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Performance Enhancing Drugs Sales Forecast (2021-2026)
12.2.2 North America: Performance Enhancing Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Performance Enhancing Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Performance Enhancing Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Performance Enhancing Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Performance Enhancing Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Performance Enhancing Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Performance Enhancing Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Performance Enhancing Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Performance Enhancing Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Performance Enhancing Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Performance Enhancing Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Performance Enhancing Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Performance Enhancing Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Performance Enhancing Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Performance Enhancing Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Performance Enhancing Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Performance Enhancing Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Performance Enhancing Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Performance Enhancing Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Performance Enhancing Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Performance Enhancing Drugs Market Segments
Table 2. Ranking of Global Top Performance Enhancing Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Performance Enhancing Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Pills
Table 5. Major Manufacturers of Injections
Table 6. Major Manufacturers of Patches
Table 7. Global Performance Enhancing Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 8. Global Performance Enhancing Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 9. Global Performance Enhancing Drugs Sales by Regions 2015-2020 (K Units)
Table 10. Global Performance Enhancing Drugs Sales Market Share by Regions (2015-2020)
Table 11. Global Performance Enhancing Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Performance Enhancing Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 13. Global Performance Enhancing Drugs Sales Share by Manufacturers (2015-2020)
Table 14. Global Performance Enhancing Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Performance Enhancing Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Performance Enhancing Drugs as of 2019)
Table 16. Performance Enhancing Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Performance Enhancing Drugs Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Performance Enhancing Drugs Price (2015-2020) (USD/Unit)
Table 19. Performance Enhancing Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Performance Enhancing Drugs Product Type
Table 21. Date of International Manufacturers Enter into Performance Enhancing Drugs Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Performance Enhancing Drugs Sales by Type (2015-2020) (K Units)
Table 24. Global Performance Enhancing Drugs Sales Share by Type (2015-2020)
Table 25. Global Performance Enhancing Drugs Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Performance Enhancing Drugs Revenue Share by Type (2015-2020)
Table 27. Performance Enhancing Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 28. Global Performance Enhancing Drugs Sales by Application (2015-2020) (K Units)
Table 29. Global Performance Enhancing Drugs Sales Share by Application (2015-2020)
Table 30. North America Performance Enhancing Drugs Sales by Country (2015-2020) (K Units)
Table 31. North America Performance Enhancing Drugs Sales Market Share by Country (2015-2020)
Table 32. North America Performance Enhancing Drugs Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Performance Enhancing Drugs Revenue Market Share by Country (2015-2020)
Table 34. North America Performance Enhancing Drugs Sales by Type (2015-2020) (K Units)
Table 35. North America Performance Enhancing Drugs Sales Market Share by Type (2015-2020)
Table 36. North America Performance Enhancing Drugs Sales by Application (2015-2020) (K Units)
Table 37. North America Performance Enhancing Drugs Sales Market Share by Application (2015-2020)
Table 38. Europe Performance Enhancing Drugs Sales by Country (2015-2020) (K Units)
Table 39. Europe Performance Enhancing Drugs Sales Market Share by Country (2015-2020)
Table 40. Europe Performance Enhancing Drugs Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Performance Enhancing Drugs Revenue Market Share by Country (2015-2020)
Table 42. Europe Performance Enhancing Drugs Sales by Type (2015-2020) (K Units)
Table 43. Europe Performance Enhancing Drugs Sales Market Share by Type (2015-2020)
Table 44. Europe Performance Enhancing Drugs Sales by Application (2015-2020) (K Units)
Table 45. Europe Performance Enhancing Drugs Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Performance Enhancing Drugs Sales by Region (2015-2020) (K Units)
Table 47. Asia Pacific Performance Enhancing Drugs Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Performance Enhancing Drugs Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Performance Enhancing Drugs Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Performance Enhancing Drugs Sales by Type (2015-2020) (K Units)
Table 51. Asia Pacific Performance Enhancing Drugs Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Performance Enhancing Drugs Sales by Application (2015-2020) (K Units)
Table 53. Asia Pacific Performance Enhancing Drugs Sales Market Share by Application (2015-2020)
Table 54. Latin America Performance Enhancing Drugs Sales by Country (2015-2020) (K Units)
Table 55. Latin America Performance Enhancing Drugs Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Performance Enhancing Drugs Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Performance Enhancing Drugs Revenue Market Share by Country (2015-2020)
Table 58. Latin America Performance Enhancing Drugs Sales by Type (2015-2020) (K Units)
Table 59. Latin America Performance Enhancing Drugs Sales Market Share by Type (2015-2020)
Table 60. Latin America Performance Enhancing Drugs Sales by Application (2015-2020) (K Units)
Table 61. Latin America Performance Enhancing Drugs Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Performance Enhancing Drugs Sales by Country (2015-2020) (K Units)
Table 63. Middle East and Africa Performance Enhancing Drugs Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Performance Enhancing Drugs Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Performance Enhancing Drugs Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Performance Enhancing Drugs Sales by Type (2015-2020) (K Units)
Table 67. Middle East and Africa Performance Enhancing Drugs Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Performance Enhancing Drugs Sales by Application (2015-2020) (K Units)
Table 69. Middle East and Africa Performance Enhancing Drugs Sales Market Share by Application (2015-2020)
Table 70. Taj Pharmaceuticals Corporation Information
Table 71. Taj Pharmaceuticals Description and Major Businesses
Table 72. Taj Pharmaceuticals Performance Enhancing Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 73. Taj Pharmaceuticals Product
Table 74. Taj Pharmaceuticals Recent Development
Table 75. Balkan Pharmaceuticals Corporation Information
Table 76. Balkan Pharmaceuticals Description and Major Businesses
Table 77. Balkan Pharmaceuticals Performance Enhancing Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. Balkan Pharmaceuticals Product
Table 79. Balkan Pharmaceuticals Recent Development
Table 80. Bayer Corporation Information
Table 81. Bayer Description and Major Businesses
Table 82. Bayer Performance Enhancing Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Bayer Product
Table 84. Bayer Recent Development
Table 85. AstraZeneca Corporation Information
Table 86. AstraZeneca Description and Major Businesses
Table 87. AstraZeneca Performance Enhancing Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. AstraZeneca Product
Table 89. AstraZeneca Recent Development
Table 90. Novo Nordisk Corporation Information
Table 91. Novo Nordisk Description and Major Businesses
Table 92. Novo Nordisk Performance Enhancing Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Novo Nordisk Product
Table 94. Novo Nordisk Recent Development
Table 95. BrainAlert Corporation Information
Table 96. BrainAlert Description and Major Businesses
Table 97. BrainAlert Performance Enhancing Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. BrainAlert Product
Table 99. BrainAlert Recent Development
Table 100. Douglas Laboratories Corporation Information
Table 101. Douglas Laboratories Description and Major Businesses
Table 102. Douglas Laboratories Performance Enhancing Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Douglas Laboratories Product
Table 104. Douglas Laboratories Recent Development
Table 105. Onnit Labs Corporation Information
Table 106. Onnit Labs Description and Major Businesses
Table 107. Onnit Labs Performance Enhancing Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Onnit Labs Product
Table 109. Onnit Labs Recent Development
Table 110. Eli Lilly And Company Corporation Information
Table 111. Eli Lilly And Company Description and Major Businesses
Table 112. Eli Lilly And Company Performance Enhancing Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. Eli Lilly And Company Product
Table 114. Eli Lilly And Company Recent Development
Table 115. Global Performance Enhancing Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 116. Global Performance Enhancing Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 117. Global Performance Enhancing Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 118. Global Performance Enhancing Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 119. North America: Performance Enhancing Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 120. North America: Performance Enhancing Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 121. Europe: Performance Enhancing Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 122. Europe: Performance Enhancing Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 123. Asia Pacific: Performance Enhancing Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 124. Asia Pacific: Performance Enhancing Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 125. Latin America: Performance Enhancing Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 126. Latin America: Performance Enhancing Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 127. Middle East and Africa: Performance Enhancing Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 128. Middle East and Africa: Performance Enhancing Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 129. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 130. Key Challenges
Table 131. Market Risks
Table 132. Main Points Interviewed from Key Performance Enhancing Drugs Players
Table 133. Performance Enhancing Drugs Customers List
Table 134. Performance Enhancing Drugs Distributors List
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
List of Figures
Figure 1. Performance Enhancing Drugs Product Picture
Figure 2. Global Performance Enhancing Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Pills Product Picture
Figure 4. Injections Product Picture
Figure 5. Patches Product Picture
Figure 6. Global Performance Enhancing Drugs Sales Market Share by Application in 2020 & 2026
Figure 7. Athletes
Figure 8. Body Builders
Figure 9. Students
Figure 10. Militaries
Figure 11. Performance Enhancing Drugs Report Years Considered
Figure 12. Global Performance Enhancing Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Performance Enhancing Drugs Sales 2015-2026 (K Units)
Figure 14. Global Performance Enhancing Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Performance Enhancing Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Performance Enhancing Drugs Sales Market Share by Region in 2019
Figure 17. Global Performance Enhancing Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Performance Enhancing Drugs Revenue Market Share by Region in 2019
Figure 19. Global Performance Enhancing Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Performance Enhancing Drugs Revenue in 2019
Figure 21. Performance Enhancing Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Performance Enhancing Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Performance Enhancing Drugs Sales Market Share by Type in 2019
Figure 24. Global Performance Enhancing Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Performance Enhancing Drugs Revenue Market Share by Type in 2019
Figure 26. Global Performance Enhancing Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Performance Enhancing Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Performance Enhancing Drugs Sales Market Share by Application in 2019
Figure 29. Global Performance Enhancing Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Performance Enhancing Drugs Revenue Market Share by Application in 2019
Figure 31. North America Performance Enhancing Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 32. North America Performance Enhancing Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Performance Enhancing Drugs Sales Market Share by Country in 2019
Figure 34. North America Performance Enhancing Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.S. Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 38. Canada Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Performance Enhancing Drugs Market Share by Type in 2019
Figure 40. North America Performance Enhancing Drugs Market Share by Application in 2019
Figure 41. Europe Performance Enhancing Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 42. Europe Performance Enhancing Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Performance Enhancing Drugs Sales Market Share by Country in 2019
Figure 44. Europe Performance Enhancing Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 46. Germany Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 48. France Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 50. U.K. Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 52. Italy Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 54. Russia Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Performance Enhancing Drugs Market Share by Type in 2019
Figure 56. Europe Performance Enhancing Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Performance Enhancing Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 58. Asia Pacific Performance Enhancing Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Performance Enhancing Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Performance Enhancing Drugs Revenue Market Share by Region in 2019
Figure 61. China Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 62. China Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 64. Japan Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 66. South Korea Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 68. India Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 70. Australia Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 72. Taiwan Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 74. Indonesia Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 76. Thailand Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 78. Malaysia Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 80. Philippines Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 82. Vietnam Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Performance Enhancing Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Performance Enhancing Drugs Market Share by Application in 2019
Figure 85. Latin America Performance Enhancing Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America Performance Enhancing Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Performance Enhancing Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Performance Enhancing Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Performance Enhancing Drugs Market Share by Type in 2019
Figure 96. Latin America Performance Enhancing Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Performance Enhancing Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa Performance Enhancing Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Performance Enhancing Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Performance Enhancing Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Performance Enhancing Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 106. U.A.E Performance Enhancing Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Performance Enhancing Drugs Market Share by Type in 2019
Figure 108. Middle East and Africa Performance Enhancing Drugs Market Share by Application in 2019
Figure 109. North America Performance Enhancing Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 110. North America Performance Enhancing Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Performance Enhancing Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. Europe Performance Enhancing Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Performance Enhancing Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Asia Pacific Performance Enhancing Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Performance Enhancing Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Latin America Performance Enhancing Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Performance Enhancing Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Middle East and Africa Performance Enhancing Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
まつげ強化剤の世界市場（～2026年） Eyelash enhancing serum is a unique formula with lash enhancement, conditioning, moisturizing, and strengthening ingredients that collaboratively works to support and improve the overall appearance of eyelashes. A plenty of temporary lash-lengthening options are available in the market such as masca…- 植物・植物由来薬剤の世界市場（～2026年） Botanical drugs are those drugs which are derived from medicinal plants. Plant derived drugs are combination of botanical as well as other approved drugs that contains plant materials, synthetic and semi synthetic substances. Botanical drugs consist of vegetable material, algae and macroscopic fungi…
- 認知・記憶増強薬の世界市場（～2026年） Cognitive enhancers are drugs and supplements, which are majorly used to treat patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. In 2017, the global Cognitive and Memory Enhancer Drugs market size was 4130 million US$ and is forec…
- 泌尿生殖器治療薬の世界市場（～2026年） A medical science concerned with the study and treatment of diseases of the genital and urinary organs, especially sexually transmitted diseases. The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of p…
- 急性反復発作薬の世界市場（～2026年） Market Analysis and Insights: Global Acute Repetitive Seizures Drugs Market The global Acute Repetitive Seizures Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Acute Repetitive Seizures Drugs Scope and Market Si…